Aesica Pharmaceuticals has entered agreements to acquire three manufacturing sites from UCB, in Monheim and Zwickau, Germany, and Pianezza, Italy. The acquisitions will nearly double the company’s capabilities in Europe and the staff across all the three sites will be maintained. Aesica has also entered a strategic partnership with UCB, consisting of a long-term supply agreement. Dr. Robert Hardy, chief executive officer of Aesica, said, “The acquisition of the three UCB manufacturing sites i...